Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:chemicalFormula |
C23H27ClF3N3O2S
|
| gptkbp:clinicalTrials |
Phase III
monotherapy BRIM-1 BRIM-2 in combination with immunotherapy BRIM-3 |
| gptkbp:contraindication |
photosensitivity
hepatotoxicity hypersensitivity reactions QT prolongation |
| gptkbp:developedBy |
Plexxikon
|
| gptkbp:drugInterdiction |
high oral bioavailability
excreted in feces induces apoptosis in cancer cells inhibits BRAF V600E mutation metabolized by CYP2C19 |
| gptkbp:hasVariants |
with other targeted therapies
with_cobimetinib |
| https://www.w3.org/2000/01/rdf-schema#label |
PLX 4032
|
| gptkbp:impact |
improves overall survival
increases response rate |
| gptkbp:interactsWith |
with MAPK pathway
with_ERK with_MEK |
| gptkbp:lastProduced |
2011
|
| gptkbp:mandates |
unresectable or metastatic melanoma
|
| gptkbp:market |
August 2011
|
| gptkbp:marketedAs |
Zelboraf
|
| gptkbp:patentStatus |
patented
|
| gptkbp:previouslyKnownAs |
vemurafenib
|
| gptkbp:releaseYear |
2007
|
| gptkbp:researchAreas |
oncology
|
| gptkbp:researchInterest |
associated with rapid tumor shrinkage
effective in BRAF V600E positive tumors improves quality of life in patients potential for use in other cancers resistance mechanisms identified |
| gptkbp:route |
oral
|
| gptkbp:sideEffect |
fatigue
nausea joint pain skin rash hair loss |
| gptkbp:targets |
BRAF mutation
|
| gptkbp:triggerType |
BRAF inhibitor
|
| gptkbp:usedFor |
treatment of melanoma
|
| gptkbp:weight |
461.03 g/mol
|